Inferior control arms in oncology trials in LMICs: contextualised or compromised?
作者信息
Teuwen Laure-Anne, Gyawali Bishal
机构信息
University Hospital Antwerp, Edegem, Flanders, Belgium.
Queen's University, Kingston, Canada.
出版信息
BMJ Oncol. 2025 Aug 25;4(1):e000931. doi: 10.1136/bmjonc-2025-000931. eCollection 2025.
Abstract
摘要
相似文献
1
Inferior control arms in oncology trials in LMICs: contextualised or compromised?低收入和中等收入国家肿瘤学试验中的下控制臂：因地制宜还是受到损害？
BMJ Oncol. 2025 Aug 25;4(1):e000931. doi: 10.1136/bmjonc-2025-000931. eCollection 2025.
2
Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional study.巴西肿瘤学随机试验中对照臂的分析：一项横断面研究。
BMJ Oncol. 2025 Aug 4;4(1):e000808. doi: 10.1136/bmjonc-2025-000808. eCollection 2025.
3
Master protocols in low- and middle-income countries: a review of current use, limitations and opportunities for precision medicine.低收入和中等收入国家的主方案：精准医学的当前应用、局限性及机遇综述
BMJ Glob Health. 2025 Jul 25;10(7):e018561. doi: 10.1136/bmjgh-2024-018561.
4
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries.低收入和中等收入国家与高收入国家当代肿瘤随机临床试验分析。
JAMA Oncol. 2021 Mar 1;7(3):379-385. doi: 10.1001/jamaoncol.2020.7478.
5
Randomization procedures in parallel-arm cluster randomized trials in low- and middle-income countries: a review of 300 trials published between 2017-2022.低收入和中等收入国家平行组群随机试验中的随机化程序：对2017年至2022年期间发表的300项试验的综述
J Clin Epidemiol. 2025 Aug;184:111825. doi: 10.1016/j.jclinepi.2025.111825. Epub 2025 May 9.
6
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.阿糖胞苷的药物基因组学与急性髓系白血病儿童及青年患者的预后
JAMA Netw Open. 2025 Jun 2;8(6):e2516296. doi: 10.1001/jamanetworkopen.2025.16296.
7
Barriers and Opportunities for Cancer Clinical Trials in Low- and Middle-Income Countries.低收入和中等收入国家癌症临床试验的障碍与机遇
JAMA Netw Open. 2025 Apr 1;8(4):e257733. doi: 10.1001/jamanetworkopen.2025.7733.
8
Patient preference trials in oncology: a scoping review and recommendations on reporting.肿瘤学中的患者偏好试验：一项范围综述及报告建议
J Clin Epidemiol. 2025 Aug;184:111837. doi: 10.1016/j.jclinepi.2025.111837. Epub 2025 May 23.
9
Assessment of whether use of a professional medical writer is associated with time to publication of papers reporting phase III oncology clinical trials in two high-impact general medicine journals.评估在两家高影响力的普通医学期刊上，使用专业医学撰写人员是否与报告肿瘤学III期临床试验的论文发表时间相关。
Curr Med Res Opin. 2025 May;41(5):887-893. doi: 10.1080/03007995.2025.2505697. Epub 2025 May 23.
10
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.早期霍奇金淋巴瘤成人患者单纯化疗与化疗联合放疗的比较
Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD007110. doi: 10.1002/14651858.CD007110.pub3.
本文引用的文献
1
Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional study.巴西肿瘤学随机试验中对照臂的分析：一项横断面研究。
BMJ Oncol. 2025 Aug 4;4(1):e000808. doi: 10.1136/bmjonc-2025-000808. eCollection 2025.
2
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.3期随机临床试验设计、分析和报告的常识性肿瘤学原则。
Lancet Oncol. 2025 Feb;26(2):e80-e89. doi: 10.1016/S1470-2045(24)00451-0.
3
Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.前列腺癌试验中的下控制臂：ARANOTE试验。
J Clin Oncol. 2025 Apr 10;43(11):1393-1394. doi: 10.1200/JCO-24-02314. Epub 2025 Jan 17.
4
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.分析 2017 年至 2021 年间发表的肿瘤随机临床试验中对照臂的充分性：一项元研究。
Eur J Cancer. 2023 Aug;189:112920. doi: 10.1016/j.ejca.2023.05.008. Epub 2023 May 15.
5
Should the control arms of randomized trials have an expiry date?随机试验的对照组应该有一个截止日期吗？
Nat Rev Clin Oncol. 2022 Jul;19(7):425-426. doi: 10.1038/s41571-022-00624-2.
6
Challenges and opportunities for cancer clinical trials in low- and middle-income countries.低收入和中等收入国家癌症临床试验面临的挑战与机遇
Nat Cancer. 2020 Feb;1(2):142-145. doi: 10.1038/s43018-020-0030-x.
7
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.高、中、低收入国家药物试验评估和新批准药物的当地商业供应情况。
JAMA Netw Open. 2021 May 3;4(5):e217075. doi: 10.1001/jamanetworkopen.2021.7075.
8
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.研究设计、实施和数据分析中的偏倚会扭曲对临床获益的评估和 ESMO-MCBS 评分。
ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20.
9
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.分析美国食品和药物管理局批准的抗癌药物随机临床试验中的对照臂质量。
JAMA Oncol. 2019 Jun 1;5(6):887-892. doi: 10.1001/jamaoncol.2019.0167.
10
Declaration of Helsinki. Ethical principles for medical research involving human subjects.《赫尔辛基宣言》。涉及人类受试者的医学研究伦理原则。
J Indian Med Assoc. 2009 Jun;107(6):403-5.
Zotero 插件